Allergy Delabeling in Antibiotic Stewardship - Intervention
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorAbramson Cancer Center at Penn Medicine
About this trial
The overall goal of the RENEW-IN intervention is to assess the impact of a BL allergy delabeling intervention on antibiotic use and clinical outcomes in patients with a hematologic malignancy.
Eligibility criteria
Qualifiers
all patients with a hematologic malignancy (including Hodgkin and non-Hodgkin lymphoma, leukemia, and myeloma) admitted to an inpatient oncology service
reported history of a beta-lactam (BL) allergy (i.e., penicillin, cephalosporin, and/or carbapenem)
Disqualifiers
patients with a history of severe cutaneous adverse reaction
patients with a history of Stevens-Johnson syndrome
patients with a history of toxic epidermal necrolysis
patients with a history of drug-induced exfoliative dermatitis
Trial design
Treatments tested in this trial
- RENEW-IN Algorithm for assessment of a beta-lactam intervention
- EMR Review
Treatment groups
3,800 Participants
are divided into 2 treatment groupsSponsors and collaborators
Abramson Cancer Center at Penn Medicine
Lead sponsor
University of Pennsylvania
Sponsor institution
University of Utah
Collaborator
Source ClinicalTrials.gov